Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.420
+0.130 (10.08%)
At close: Jun 6, 2025, 4:00 PM
1.430
+0.010 (0.70%)
After-hours: Jun 6, 2025, 7:20 PM EDT
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
n/a
Profits / Employee
-$1,101,847
Market Cap
310.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ALLO News
- 5 days ago - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - GlobeNewsWire
- 8 days ago - Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
- 9 days ago - Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
- 14 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - GlobeNewsWire
- 23 days ago - Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire